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This general commentary on the above, recently published New England Journal of Medicine review 
article wishes to clarify both the nomenclature as well as the role of autoantibodies (Ab) to the TSH 
receptor (TSH-R) pertaining to the serological diagnosis of Graves’ disease (GD).
Various terms have been used to describe the different types of TSH-R-Ab. It is important for 
the clinician to be aware of the different nomenclature as this will frequently reflect which assay is 
performed by the laboratory (Table 1). TSH-R-Ab, often referred to as TRAb, refers to any type of Ab 
interacting specifically with the TSH-R. Because these Ab are commonly assessed in a competitive 
binding assay, they are referred to as TSH-R-binding inhibitory immunoglobulins (TBII). By contrast, 
cell-based bioassays measure either TSH-R stimulatory antibodies (TSAb) or TSH-R-stimulating 
immunoglobulins, or alternately TSH-R-blocking antibodies (TBAb) or TSH-R-blocking immuno-
globulins. Alternative terminologies for blocking antibodies are TSH-R-stimulating blocking Ab or 
TSH-R-blocking Ab (TRBAb). In this commentary, we will use TSH-R-Ab as a general term to refer 
to anti-TSH-R-Ab irrespective of the specific assay used. We will use TBII to refer to the Ab measured 
via binding assays, whereas Ab measured via bioassays will be referred to as TSAb for stimulatory 
and TBAb for blocking Ab.
Graves’ disease is caused by persistent, unregulated stimulation of thyroid cells by TSH-R-
stimulating Ab (TSAb) that activate the TSH-R (1). TSAb, like TSH, bind primarily to the large amino 
terminal ectodomain of the TSH-R and activate the cAMP signal transduction pathway leading to 
stimulation of thyroid hormone production and proliferation of thyrocytes. Since the discovery of 
TSAb as the causative agent of GD, there have been numerous studies that have demonstrated the 
significance of the levels of these Ab during the course of the disease as well as during antithyroid 
drug treatment in both adults and children (2, 3). Other types of TSH-R antibodies can antagonize 
or block the action of TSH and in doing so cause hypothyroidism in certain patients with various 
types of autoimmune thyroiditis, particularly Hashimoto’s thyroiditis. TSH-R antibodies that neither 
induce the cAMP signal pathway nor block the binding of TSH are referred to as neutral or recently 
“cleavage” Ab and currently are not known to have a functional effect (4). There is evidence, however, 
that neutral Ab may induce signaling pathways distinct from the cAMP pathway and may induce 
apoptosis (5).
As strongly recommended in the recently published hyperthyroidism guidelines of the American 
Thyroid Association (6), measurement of TSH-R-Ab is indicated both for the accurate and early 
diagnosis of autoimmune induced hyperthyroidism as well as during the management of patients 
with GD. Functional TSH-R-stimulating antibodies (TSAb) are causative of both the hyperthyroidism 
and the extra thyroidal manifestations of GD (7). TSAb can be sensitively and exclusively measured 
table 1 | terminology for tSH receptor antibodies used in bioassays and 
binding assays.
abbreviation
Cell-based bioassay
•	 TSH-R-stimulating antibodies
•	 TSH-R-stimulating immunoglobulins
•	 TSH-R-blocking antibodies
•	 TSH-R-stimulating blocking antibodies
•	 TSH-R-blocking immunoglobulins
TSAb
TSI
TBAb, TSB-Ab, or TRBAb
TRBAb
TBI
Competitive-binding assay
•	 TSH-R-binding inhibitory immunoglobulins TBII
2
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with validated bioassays that are available worldwide (8–11). In 
particular, the analytical performance and clinical utility of a 
FDA-cleared, stimulatory TSH-R bioassay in a large collective of 
patients with GD, both prior to as well as during medical antithy-
roid treatment, has been shown (12). In addition, a multicenter 
trial involving seven American and European academic referral 
centers confirmed the very high specificity, sensitivity, and posi-
tive and negative predictive values of this tool for the diagnosis 
of GD in children (13). Standardization and calibration of this 
bioassay, using a purely stimulatory human monoclonal TSH-
R-Ab as international standard, allowed results to be reported in 
international units per liter (14). This has facilitated comparison 
of bioassay results with commercially available automated TSH-
R-binding or TBII assays. A recent comparative study of seven 
immunoassays has shown that bioassays for TSH-R-Ab are more 
sensitive than the automated binding assays and exclusively 
differentiate between stimulatory and blocking Ab activity (15). 
Also, TSAb are a highly sensitive and predictive biomarker of the 
extra thyroidal manifestations of GD (16–18). Furthermore, the 
clinical relevance of the measurement of TSH-R-Ab and of TSAb 
in particular, during pregnancy in patients with autoimmune thy-
roid disease, was recently documented in a newborn with fetal/
neonatal autoimmune thyrotoxicosis (19). Finally, incorporation 
and early utilization of TSAb into current diagnostic algorithms 
was shown to confer a 46% shortened time to diagnosis of GD and 
a cost savings of 47% (20).
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